Dear All, If you’re going to be in New York City on 23 Sep for the UN General Assembly, you are invited to join U.S. Health and Human Services Secretary, Alex Azar, experts from the U.S. Centers for Disease Control and Prevention, and hundreds of organizational and global leaders at an evening celebrating global AMR
Dear All, Two mid-week notes: First (and huge!), India’s Ministry of Health issued a notification last week prohibiting the “manufacture, sale and distribution of the drug colistin and its formulations for food-producing animals, poultry, aqua farming and animal feed supplements” because such use is “likely to involve risk to human beings.” You can find this on multiple
Dear All: There are days when I have the feeling of drinking from a fire hose … and this is one of them! Multiple interesting new events have crossed my radar in the past 48 hours with topics that span AMR Awareness (two events in Geneva next week!), CNS infections (Rockville, MD), an EMA info-day
Dear All: Potpourri! Four things of note… First, Pew’s SPARK (Shared Platform for Antibiotic Research and Knowledge) has now gone live. Seeking to address a core issue in Pew’s Scientific Roadmap for Antibiotic Discovery, SPARK is a cloud-based sharing tool for data on how molecules enter and stay inside of Gram-negative bacteria. To learn more, mark your calendar
For those based in Boston, please look closely at the future meetings list: a 7 Dec 2018 BAARN meeting date has been announced. Dear All: On 21 Nov 2018, the Decision Support Unit (DSU) of UK NICE and the ABPI are sponsoring a one-day workshop entitled “NICE/DSU/ABPI Masterclass: Using non-randomised data to estimate treatment effects
Dear All: EU’s IMI (Innovative Medicine Initiative) has initiated a new accelerator program for AMR-focused products! I added the links in the last newsletter … now it’s time for the details. (And separately please also note that there are 6 new meetings in the future meetings list … look closely … it is impossible to keep up!) This new
Dear All, Please mark your calendar now to be in the Washington, DC area on 18-19 Nov 2019 for a 2-day workshop at FDA’s White Oak Campus focused on enhancing the clinical trial enterprise for antibacterial drug development. Jointly co-sponsored by FDA, IDSA, NIAID, and Pew Trusts, this meeting will have a particular focus on (a)
Dear All: Two things on a Friday: First, I just learned of IDSA’s release of its latest paper (link) in the Bad Bugs/No Drugs and 10×20 series. Officially entitled “The Infectious Diseases Society of America’s 10 × ’20 Initiative (Ten New Systemic Antibacterial Agents FDA-approved by 2020): Is 20 × ’20 a Possibility?”, I think a
Dear All: The United Kingdom Science and Innovation Network (UK-SIN), the United States Centers for Disease Control and Prevention (US-CDC), and the Wellcome Trust (WT) have recently released a white paper highlighting the potential for the environment (e.g., soil and water) to be a source of antimicrobial-resistant microbes that can affect human health: Executive Summary: Initiatives
Dear All, Two time-limited opportunities have been announced in the past few days. First, the Novo REPAIR Impact Fund has opened its 2019 US-Canada-focused investment round. Non-confidential proposals are due by 11 Oct … go here for details. Note that you need to dig all the way to the bottom of the web page to find the information.